Age and Latent Cytomegalovirus Infection Do Not Affect the Magnitude of De Novo SARS‐CoV‐2‐Specific CD8 <sup>+</sup> T Cell Responses
Immunosenescence, age-related immune dysregulation, reduces immunity upon vaccinations and infections. Cytomegalovirus (CMV) infection results in declining naïve (T<sub>naïve</sub>) and increasing terminally differentiated (T<sub>emra</sub>) T cell populations, further aggravating immune aging. Both immunosenescence and CMV have been speculated to hamper the formation of protective T-cell immunity against novel or emerging pathogens. The SARS-CoV-2 pandemic presented a unique opportunity to examine the impact of age and/or CMV on the generation of de novo SARS-CoV-2-specific CD8<sup>+</sup> T cell responses in 40 younger (22-40 years) and 37 older (50-66 years) convalescent individuals. Heterotetramer combinatorial coding combined with phenotypic markers were used to study 35 SARS-CoV-2 epitope-specific CD8<sup>+</sup> T cell populations directly ex vivo. Neither age nor CMV affected SARS-CoV-2-specific CD8<sup>+</sup> T cell frequencies, despite reduced total CD8<sup>+</sup> T<sub>naïve</sub> cells in older CMV<sup>-</sup> and CMV<sup>+</sup> individuals. Robust SARS-CoV-2-specific central memory CD8<sup>+</sup> T (T<sub>cm</sub>) responses were detected in younger and older adults regardless of CMV status. Our data demonstrate that immune aging and CMV status did not impact the SARS-CoV-2-specific CD8<sup>+</sup> T cell response. However, SARS-CoV-2-specific CD8<sup>+</sup> T cells of older CMV<sup>-</sup> individuals displayed the lowest stem cell memory (T<sub>scm</sub>), highest T<sub>emra</sub> and PD1<sup>+</sup> populations, suggesting that age, not CMV, may impact long-term SARS-CoV-2 immunity.
Authors
- S. Marieke van Ham (ORCID: https://orcid.org/0000-0003-1999-9494)
- Jet van den Dijssel (ORCID: https://orcid.org/0000-0002-4849-0374)
- Mariël C Duurland
- René A. W. van Lier (ORCID: https://orcid.org/0000-0002-3201-7144)
- Julian J. Freen‐van Heeren (ORCID: https://orcid.org/0000-0003-0506-2756)
- C. Ellen van der Schoot (ORCID: https://orcid.org/0000-0002-8065-3540)
- Klaas P. J. M. van Gisbergen (ORCID: https://orcid.org/0000-0003-3623-7555)
- Veronique A. L. Konijn
- Barbera Veldhuisen (ORCID: https://orcid.org/0000-0003-2898-7444)
- Theo Rispens (ORCID: https://orcid.org/0000-0001-9600-1312)
- Rivka de Jongh
- Maurice Steenhuis (ORCID: https://orcid.org/0000-0003-1322-5869)
- Carolien E. van de Sandt (ORCID: https://orcid.org/0000-0002-4155-7433)
- Lianne Koets (ORCID: https://orcid.org/0000-0002-2845-5694)
- Anja ten Brinke (ORCID: https://orcid.org/0000-0002-0135-7496)
- Annelies W. Turksma
- Hilde Raaphorst
Institutions
- Champalimaud Foundation (PT)
- The University of Melbourne (AU)
- University Medical Center Utrecht (NL)
- Sanquin (NL)
- Peter Doherty Institute (AU)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- European Journal of Immunology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/eji.202451565
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Melbourne
- Australian Research Council